Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

TY - JOUR

T1 - Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

AU - Grunnet, Mie

AU - Christensen, Ib J

AU - Lassen, Ulrik

AU - Jensen, Lars H

AU - Lydolph, Magnus

AU - Knox, Jennifer J

AU - McNamara, Mairead G

AU - Jitlal, Mark

AU - Wasan, Harpreet

AU - Bridgewater, John

AU - Valle, Juan W

AU - Mau-Sørensen, Morten

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/7

Y1 - 2015/7

N2 - Background: Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer. Methods: Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.

AB - Background: Carbohydrate associated antigen (CA19-9) has been approved by the FDA as a biomarker for monitoring treatment effect in pancreatic cancer. However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer. Methods: Consecutive patients with inoperable bile duct cancer treated at a University Hospital were retrospectively included in an investigational cohort (n = 212). Three validation cohorts were established including patients 1) participating in phase I/II trials at a Danish Hospital (n = 71), 2) identified retrospectively in a Canadian cohort (n = 196) and 3) randomized in the ABC-02 trial (n = 410). Patients with a baseline CA19-9 and at least one CA19-9 value measured 10-12 weeks after the start of chemotherapy were included. Multivariate Cox regression analyses were performed.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Bile Duct Neoplasms

KW - CA-19-9 Antigen

KW - Clinical Trials, Phase I as Topic

KW - Clinical Trials, Phase II as Topic

KW - Cohort Studies

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Prospective Studies

KW - Randomized Controlled Trials as Topic

KW - Retrospective Studies

KW - Survival Analysis

U2 - 10.1016/j.ejca.2015.04.011

DO - 10.1016/j.ejca.2015.04.011

M3 - Journal article

C2 - 25971532

SN - 0959-8049

VL - 51

SP - 1381

EP - 1388

JO - European journal of cancer (Oxford, England : 1990)

JF - European journal of cancer (Oxford, England : 1990)

IS - 11

ER -